Paul Saladino· MD
we also know that the inhibition of HMG Co reductase in the mevalonate pathway leads to decreased levels of doal that can negatively affect both the positioning and the actions of the insulin receptor in cell membranes
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we also know that the inhibition of HMG Co reductase in the mevalonate pathway leads to decreased levels of doal that can negatively affect both the positioning and the actions of the insulin receptor in cell membranes
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.